Heidelberg Pharma

Heidelberg Pharma is a biopharmaceutical company that is listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. The Company was founded by a team of physicians and oncologists from the Technical University of Munich. The Company had changed to an AG from a GmbH legal structure in 200. In 2011, the subsidiary Heidelberg Pharma Research GmbH was acquired.

Heidelberg Pharma became restructured in 2014, which led to the discontinuation of all research and development activities in Munich. At the shareholder’s meeting in July 2017, a decision was made to move the registered office of WILEX AG from Munich to Ladenburg and change the company's name to Heidelberg Pharma AG. The subsidiary Heidelberg Pharma GmbH has now been named Heidelberg Pharma Research GmbH.

Heidelberg Pharma is a company that focuses on oncology and it is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate technology platform, and it advances the biological mode of action of the toxin as a novel therapeutic principle.

It proprietary platform is being applied to develop the company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. Its proprietary lead candidate, HDP-101, is a BCMA-ATAC for multiple myeloma. Heidelberg Pharma provides preclinical contract research services.